The epidemiology of HIV in the Asia-Pacific region reflects local drivers of infection (e.g., male-to-male sex, injection drug use), key co-infections that impact treatment outcomes (e.g., hepatitis B and 0, tuberculosis), and a range of treatment access and national resource levels. In addition, emerging evidence suggests that the pharmacology and toxicity of antiretroviral drugs in Asian populations are significantly different from Caucasian patients, which could impact long-term treatment tolerability and success. The overall goal of the Asia-Pacific HIV Research Collaboration is to evaluate the impact of HIV disease, co-infections, and ART management on clinical outcomes in the region. Research builds on existing scientific capacity for both broad regional and multiregional analyses and targeted studies on specific outcomes of interest within at-risk populations. The core research relies upon data from the Asia-Pacific HIV Observational Database (APHOD), comprised of the TREAT Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). Core research also includes the TREAT Asia Pediatric HIV Observational Database (TApHOD). These three established cohorts include data from 60 clinical centers at 54 institutions in 14 South, Southeast and East Asian countries and Australia. A separate collaboration with the National Center for AIDS/STD Control and Prevention (NCAIDS), China CDC, will conduct epidemiologic studies using the China National ART Database, a national surveillance program. Data collection will expand current studies in several innovative areas, with specific aims looking at factors driving the epidemic, as well as the response to ART, impact of co-infections, toxicity of first- and second-line regimens, cancer risk, chronic AIDS- and non-AIDS-related events and outcomes, drug resistance patterns, and cultural and behavioral factors affecting patient management and outcomes. The inclusion of research sites from a wide variety of geographic and socio-economic settings will continue to strengthen the existing adult and pediatric research networks. Successful implementation of these studies will build up an evidence base to inform HIV clinical management practices and programs, advise national and regional treatment guidelines, and add to global understanding of the epidemiology of HIV.

Public Health Relevance

Published findings on short- and long-term HIV treatment outcomes will lead to more effective, evidence- based clinical management practices for HIV-infected adults and children in the Asia-Pacific region. Identifying risk factors for cancer will help guide future prevention and screening efforts. Participating sites will gain capacity to expand local and regional research activities to better understand the epidemiology of HIV.

National Institute of Health (NIH)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Zimand, Lori B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Foundation for AIDS Research
New York
United States
Zip Code
Sabin, Caroline A; Reiss, Peter; Ryom, Lene et al. (2016) Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med 14:61
Boettiger, David C; Sabin, Caroline A; Grulich, Andrew et al. (2016) Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS 30:1629-37
Durier, N; Yunihastuti, E; Ruxrungtham, K et al. (2016) Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia. J Viral Hepat :
Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD, and COHERE in EuroCoord (2016) Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clin Infect Dis 63:1245-1253
Achhra, A C; Mocroft, A; Reiss, P et al. (2016) Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med 17:255-68
Charles, M Katherine; Lindegren, Mary Lou; Wester, C William et al. (2016) Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One 11:e0153243
Mulhall, B P; Wright, S T; De La Mata, N et al. (2016) Risk factors associated with incident sexually transmitted infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. HIV Med 17:623-30
Boettiger, David C; Khol, Vohith; Durier, Nicolas et al. (2016) HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. Antivir Ther :
Prasitsuebsai, Wasana; Teeraananchai, Sirinya; Singtoroj, Thida et al. (2016) Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia. J Acquir Immune Defic Syndr 72:380-6
Friis-Møller, Nina; Ryom, Lene; Smith, Colette et al. (2016) An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol 23:214-23

Showing the most recent 10 out of 172 publications